Decreased frequency of adenoidectomy by a 12-week nasal budesonide treatment
Authors Hong H, Chen F, Zheng X, Liao W, Liao Z, Cao Y, He H, Zhu Z, Fan Y
Received 22 June 2017
Accepted for publication 7 August 2017
Published 3 October 2017 Volume 2017:13 Pages 1309—1316
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Professor Deyun Wang
Haiyu Hong,1,* Fenghong Chen,2,* Xiaobin Zheng,3 Wei Liao,1 Zhenpeng Liao,1 Yujie Cao,2 Haixin He,1 Zhe Zhu,4,5 Yunping Fan1
1Department of Otolaryngology and Head Neck Surgery of 5th Hospital, Affiliated with Sun Yat-sen University, Zhuhai, 2Department of Otolaryngology and Head Neck Surgery of 1st Hospital, Affiliated with Sun Yat-sen University, Guangzhou, 3Department of Respiration of 5th Hospital, Affiliated with Sun Yat-sen University, Zhuhai, China; 4Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 5Sanford Consortium, Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA
*These authors contributed equally to this work
Objective: There is little evidence on the role of topical budesonide in reducing the frequency of adenoidectomy, although it was reported that topical budesonide can effectively ameliorate the symptoms of adenoid hypertrophy (AH). This study was aimed to investigate the possibility and safety of alternatives to adenoidectomy with a 12-week treatment with nasal budesonide.
Materials and methods: One hundred patients with AH were randomized to receive either a double-blind budesonide (1 mg once daily) or placebo treatment for 2 weeks by transnasal nebulization. A further 12-week open study, budesonide spray (64 µg per nostril at bedtime) was administered to the treatment group. During the final 12 weeks of follow-up, the frequency of adenotonsillectomy, side effects, the degree of nasal obstruction, nasal discharge, and snoring were assessed.
Results: Out of the 100 total enrolled patients, 92 children with AH completed the study. After the 2-week treatment with transnasal budesonide nebulization, the symptoms of AH significantly decreased compared to the control group. Responders (n=26) who had initially improved showed significantly decreased symptoms of AH, and the frequency of adenotonsillectomy during the follow-up (14 and 26 weeks) was compared with that of the control group and non-responders (n=21) who did not respond to the initial 2-week budesonide therapy. The 12-week nasal budesonide treatment did not suppress the growth rate of children’s height or cause other side effects.
Conclusion: AH children who had improved after an initial 2-week budesonide therapy can achieve clinical improvements and decreased frequency of adenoidectomy following the therapy with a 12-week treatment with nasal budesonide.
Keywords: adenoid hypertrophy, adenoidectomy, budesonide, frequency, treatment
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]